^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Debio 0123

    i
    Other names: Debio 0123, Debio-0123, Debio0123
    Associations

    News

    Trials
    Company:
    Almac Discovery, Debiopharm
    Drug class:
    WEE1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    8d
    WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=76, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
    8d
    Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=76, Terminated, Debiopharm International SA | Trial completion date: Nov 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2027 --> Oct 2025; This trial was concluded for strategic reasons.
    Trial completion date • Trial termination • Trial primary completion date
    |
    carboplatin • Debio 0123
    12d
    Debio 0123-SCLC-104: Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Debiopharm International SA | Trial completion date: Jul 2026 --> Feb 2026
    Trial completion date
    |
    carboplatin • etoposide IV • Debio 0123
    30d
    Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting | N=78 --> 34
    Enrollment closed • Enrollment change
    |
    carboplatin • etoposide IV • Debio 0123
    1m
    A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=155, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Debio 0123
    5ms
    Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
    P1, N=78, Recruiting, Debiopharm International SA | Trial completion date: Apr 2026 --> Jul 2026
    Trial completion date
    |
    carboplatin • etoposide IV • Debio 0123
    7ms
    Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=76, Active, not recruiting, Debiopharm International SA | N=115 --> 76
    Enrollment change
    |
    carboplatin • Debio 0123
    10ms
    Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=115, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • Debio 0123
    11ms
    WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, MedSIR | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
    12ms
    Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=115, Recruiting, Debiopharm International SA | Trial completion date: Apr 2027 --> Nov 2027 | Trial primary completion date: Jun 2025 --> Nov 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    carboplatin • Debio 0123
    1year
    WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, MedSIR
    New P1/2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
    over1year
    Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
    P1, N=78, Recruiting, Debiopharm International SA | N=54 --> 78
    Enrollment change
    |
    carboplatin • etoposide IV • Debio 0123